Pulmonary Embolism

Rivaroxaban, a novel oral anticoagulant, plays an important role in the prevention and treatment of thromboembolic diseases. Compared with traditional anticoagulants, rivaroxaban has the characteristics of definite curative effect, good safety, convenient use, and no need to monitor blood coagulation indicators frequently. It is widely used in hip (or knee) joint replacement, deep vein thrombosis, […]

On 12 December, Daiichi Sankyo announced the results of a pooled analysis showing that edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty, when compared to enoxaparin.  Patients receiving edoxaban had a lower incidence of a composite of deep vein thrombosis […]

Generic: Rivaroxaban Brand Name: Xarelto Classification: Anticoagulants, antithrombotic, factor Xa inhibitors Therapeutic use: Prevention, treatment of, and reduction of deep vein thrombosis that may lead to pulmonary embolism following knee or hip replacement surgery. Reduction in risk of stroke Action: Acts as selective factor X inhibitor that blocks the active site of factor Xa, inactivating […]

Daiichi Sankyo announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies. The findings of the two subgroup analyses of 1,943 East Asian patients (Japan, mainland China, Korea and Taiwan) enrolled in the ENGAGE AF-TIMI 48 study and 1,101 […]

Apirax® Generic name: Apixaban Pharmacologic Category: Anticoagulant Dosage Forms: Tablet, Oral (2.5 mg, 5 mg) Description: Apixaban is a selective inhibitor of FXa. Apixaban inhibits free and clot-bound FXa and indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development Indications: Reduction of risk of stroke and […]

Generic Drug Name: Heparin Drug Classification : Therapeutic class – anticoagulant Pharmacologic class – anticoagulant Location of metabolism/excretion: Metabolism – Liver Excretion – Urine/Kidneys Nursing Implications/Assessment: History – thromboprophylaxis, DVT, MI, PE, embolisms associated with atrial fibrillation, venous thrombosis, hyperlipidemia, pregnancy Physical – peripheral pulses/perfusion, blood tests, kidney function tests, platelet count, prevention of injury […]

Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis, and pulmonary embolism. Medication Pearl of the Day: Rivaroxaban (Xarelto) Indication: Rivaroxaban is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular […]

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial – Fingerprint — University of Edinburgh Research Explorer Sort by Weight Alphabetically Medicine & Life Sciences Rivaroxaban 100% Aortic Diseases 94% Warfarin 80% Mitral Valve 76% Aortic […]

Introduction: Sickle cell disease (SCD) is a hematological disorder characterized by sickling of red blood cells. Patients are at increased risk of venous thromboembolism. There are no guidelines for the management of venous thromboembolism in sickle cell disease specifically in terms of the anticoagulant of choice. Patient concerns: Here, we report a case of a […]

Primary outcomes included all-cause hospitalization, stroke and major bleeding, stroke and systemic embolism. Overall, the authors found that the adjusted hazard ratio from the meta-regression analyses was 0.88 to 0.95, indicating a significantly lower hazard of stroke/systemic embolism associated with apixaban compared with rivaroxaban. The authors also found that pair-wise meta-analyses showed that the pooled […]

This article was originally published here Am J Cardiovasc Drugs. 2021 Dec 20. doi: 10.1007/s40256-021-00514-5. Online ahead of print. ABSTRACT BACKGROUND: The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician’s discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. […]

Hematologic Flashcards | Quizlet   heparinwarfarin Factor Xa inhibitors -Myocardial infarction-ischemic stroke-DVT/PE-atrial fibrillation -after surgery-extended immobilization -treat DVT-MOA: increase antithrombin activity which binds and inactivates clotting factors (thrombin, IXa, Xa)-IV or injection: rapid onset -MUST monitor INR, partial thromboplastin, and platelets -side effects: bleeding (thrombocytopenia) -treat long term prevention of DVT and treat a-fib-MOA: interferes […]

Quick Takes More than 36,000 patients with VTE newly starting apixaban or rivaroxaban were compared and followed for >3 months using medical claims. Use of apixaban was associated with a lower risk of intracranial or gastrointestinal bleeding as compared to rivaroxaban therapy. Use of apixaban was associated with a lower risk of recurrent VTE as […]

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Medication Pearl of the Day: Dabigatran Etexilate (Pradaxa) Indication: Dabigatran etexilatecapsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in […]

False Question 2 0 out of 10 points Please use the nomogram… Image transcription text False Question 2 0 out of 10 points Please use the nomogram provided in the Anticoagulants PPT for reference. You patient is on a heparin infusion for treatment of a pulmonary embolism. Pt weight 220 pounds. Your patient is currently […]

This article was originally published here Res Pract Thromb Haemost. 2021 Nov 30;5(8):e12604. doi: 10.1002/rth2.12604. eCollection 2021 Dec. ABSTRACT BACKGROUND: Patients with cancer-associated thrombosis (CAT) have a high risk of recurrent venous thromboembolic events, which contribute to significant morbidity and mortality. Direct oral anticoagulants may provide a convenient treatment option for these patients. OBJECTIVES: To […]

Patients with venous thromboembolism (VTE) who received apixaban had a lower rate of recurrence, as well as intracranial and gastrointestinal bleeding events, compared with those treated with rivaroxaban, a recent study found. The retrospective new-user cohort study used a U.S.-based commercial health care insurance database to compare outcomes between patients with VTE who were newly […]

Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. Objective: To assess the effectiveness and safety of apixaban compared with rivaroxaban in patients with VTE. Design: Retrospective new-user cohort study. Setting: U.S.-based commercial health care insurance database from 1 January 2015 […]

The tentatively approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Pradaxa Dabigatran Etexilate Mesylate capsules, Eq to 150 mg base, Boehringer Ingelheim Read Article Alembic Pharmaceuticals yesterday announced that it has received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dabigatran […]